Investing.comCodex · 实盘不做把握 8/10
北京时间·🕒 发布 04:17:15时区推断·⟳ 抓取 04:17:58·⚡ 决策 07-24 04:19:12 +1m14s·95.6 天前
Abivax为obefazimod潜在商业化任命四名商业高管
本次只是商业团队任命，核心药物obefazimod仍处于三期且NDA计划在2026年四季度提交，未披露疗效、监管、销售或资金层面的新增结果。
📄 原文Investing.com↗ 原文
Abivax appoints four executives ahead of drug application
Nasdaq falls over 2% as stocks slide on Alphabet, Tesla drag, surging oil prices PARIS - Abivax SA (Euronext Paris:ABVX…
不做 Abivax（ABVX.US）
仅为商业高管任命和未来NDA准备，不是临床读出、监管获批、提交受理或商业销售节点，缺乏短期可交易edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-23 · 扩散 low · price-in 风险 medium ↗
关键理由
- 本次只是商业团队任命，核心药物obefazimod仍处于三期且NDA计划在2026年四季度提交，未披露疗效、监管、销售或资金层面的新增结果。
- 高管履历有助于商业化准备，但对未来1-10个交易日收入、利润或监管成功率没有可量化的直接增量。
主要风险
- 若后续出现三期读出、NDA正式提交或FDA受理/优先审评等离散监管节点，需要作为新催化重新研判。
原文全文
展开原文 · 1,750 字
Nasdaq falls over 2% as stocks slide on Alphabet, Tesla drag, surging oil prices
PARIS - Abivax SA (Euronext Paris:ABVX / NASDAQ:ABVX) announced today the appointment of four executives to its commercial leadership team as the company prepares to submit a New Drug Application for obefazimod to the U.S. Food and Drug Administration in the fourth quarter of 2026.
The biotechnology company named James Berger as Global Head of Marketing, Ivan Nuñez-Pacheco as Global Head of Patient Services, Heather Dean as Global Head of Sales, Accounts & Commercial Operations, and Jeff Haas as Global Head of Market Access & Pricing, according to a press release statement.
Berger previously served as Global Franchise Head for TEZSPIRE at Amgen and spent over a decade at Takeda working on ENTYVIO. Nuñez-Pacheco joins from AbbVie, where he led patient services for HUMIRA, SKYRIZI, and RINVOQ. Dean held leadership positions at Eli Lilly and Takeda, including oversight of ENTYVIO’s commercial teams and Takeda’s Neuroscience Business Unit. Haas served as Corporate Vice President at Abbott Laboratories and held senior roles at AbbVie, including work on HUMIRA’s market access strategy.
Michael Nesrallah, Chief Commercial Officer of Abivax, stated the appointments strengthen the company’s commercial organization as it prepares for potential U.S. commercialization of obefazimod.
Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases. Obefazimod is currently in Phase 3 clinical trials for moderately to severely active ulcerative colitis.
The company is based in France and the United States.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
PARIS - Abivax SA (Euronext Paris:ABVX / NASDAQ:ABVX) announced today the appointment of four executives to its commercial leadership team as the company prepares to submit a New Drug Application for obefazimod to the U.S. Food and Drug Administration in the fourth quarter of 2026.
The biotechnology company named James Berger as Global Head of Marketing, Ivan Nuñez-Pacheco as Global Head of Patient Services, Heather Dean as Global Head of Sales, Accounts & Commercial Operations, and Jeff Haas as Global Head of Market Access & Pricing, according to a press release statement.
Berger previously served as Global Franchise Head for TEZSPIRE at Amgen and spent over a decade at Takeda working on ENTYVIO. Nuñez-Pacheco joins from AbbVie, where he led patient services for HUMIRA, SKYRIZI, and RINVOQ. Dean held leadership positions at Eli Lilly and Takeda, including oversight of ENTYVIO’s commercial teams and Takeda’s Neuroscience Business Unit. Haas served as Corporate Vice President at Abbott Laboratories and held senior roles at AbbVie, including work on HUMIRA’s market access strategy.
Michael Nesrallah, Chief Commercial Officer of Abivax, stated the appointments strengthen the company’s commercial organization as it prepares for potential U.S. commercialization of obefazimod.
Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases. Obefazimod is currently in Phase 3 clinical trials for moderately to severely active ulcerative colitis.
The company is based in France and the United States.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。